SlideShare una empresa de Scribd logo
1 de 43
Descargar para leer sin conexión
WORKSHOP ON
PRESCRIBING FOR CHILDREN AND ADOLESCENTS:
PERSPECTIVE FROM LOW RESOURCE COUNTRY
Devashish Konar Consultant Psychiatrist & Director
Mental Health Care Centre, Kolkata & Burdwan, India
120 September 2016, Calgary
LEARNING OBJECTIVES:
• Stimulating people to find ways to cater treatment in
low resource countries.
• In countries where Child Psychiatrists are scarce,
simplifying basic concepts of paediatric
psychopharmacology to educate other professionals,
who need to be involved in the treatment of
unreached psychologically ill children.
2
FIVE SIMPLE QUESTIONS IN RELATION TO CHILD
AND ADOLESCENT PSYCHOPHARMACOLOGY
1. As compared to adult, liver is:
A. More Active
B. Less Active
2. As compered to adult, elimination (weight adjusted clearance) through kidneys is:
A. Faster
B. Slower
3. Research Unit of Pediatric Psychopharmacology (RUPP) has been formed under leadership of:
A. Royal College of Psychiatrist, London
B. National Institute of Mental Health
C. United States Food and Drug Administration
4. Blood brain barrier in children is:
A. Less permeable
B. More permeable
5. As compared to adult, metabolic side effects of antipsychotics are:
A. More common
B. Less common
3
BEFORE WORKSHOP AFTER WORKSHOP
ECONOMIC CLASSIFICATIONS OF COUNTRIES OF THE WORLD:
•High resource
•Low resource
Developed
Developing
Underdeveloped
4
First World
Second World
Third World Country
TWO DISTINCT WORLDS
HIGH RESOURCE
Where there are many child psychiatrists,
and a team working with the children.
Burning issue

5
Are we prescribing more?
LOW RESOURCE
Where there are very few child psychiatrists, and
there is hardly any team working with children.
Burning Issue

6
Are we able to reach children who need treatment?
??? TEAM WORK ???
IN LOW RESOURCE COUNTRIES
Do we need team work?
Is it the same team we are talking about as in high resource countries?
Whom to educate?
What to educate?
How to make a team?
7
CASE VIGNETTE
A child of 13 years sleeping excessively, yawning when awake, nagging, clinging,
irritable, demanding & destructive. Illness started following a brief febrile illness.
Earlier had similar episode 8 months back.
What would you specifically want to know about this case?
- History of bipolarity in the family
- Thyroid status
- Psychosocial stressor
(+)
(-)
8
(-)
HOW DO YOU MANAGE?
Take proper history
Psycho-education about bipolarity
Start treatment in a way that mania is not precipitated
All medicines to be built up slow
Frequent follow up visits
Support yourself with investigation related to treatment
Plan prolonged follow-up
9
FEW DRUGS LICENSED
Historically, pediatric pharmacology in general and pediatric
psychopharmacology in particular have received much less research
interest and funding than their adult counterparts.
As a consequence, relatively few drugs are licensed for use in child and
adolescent populations. (Coghill & Sinita 2014)
There is growing evidence base of increasingly widespread practice of
using psychopharmacological treatment in children and adolescents.
(Huline-Dickens 2014)
10
CHILDHOOD PSYCHIATRIC ILLNESSES ARE NOT TRIVIAL ONES
Childhood and adolescence is a period of extraordinary biological, psychological and
social growth.
However, at such times, individuals are also vulnerable to disruptions of healthy
development.
In fact, a staggering 50% of all adult psychiatric disorders have manifested by age 14,
with 75% manifesting by age 24.
Moreover, two thirds of pediatric-onset psychiatric disorders are moderate or severe,
and most continue into adulthood.
Such pattern clearly indicate the importance of identifying and appropriately treating
psychiatric disorders as early as possible to preserve healthy development and to
reduce individual suffering and societal burden.
(Correll et al 2013)
11
SHIFT TO COLLABORATIVE CARE
Mental health issues are being recognized more and more at an earlier age.
Issue is alarming, at the same time recognizing them early is good for the child.
The shortage of clinicians with specialized training is always the main constraint
in case of low resource countries.
Medication may become important part of treatment.
Judicious evidence based prescribing, slow titration and never, ever,
over-prescribing, should be the mantra to succeed in treating children.
Medication is only one piece of treatment plan, but relying on it may be in need if
other trained personnel are not available.
12
CONSULTATION SHOULD BE EARLY, TREATMENT JUDICIOUS
One of the most important need in case of child mental health is facilitation of
earlier psychiatric consultation.
Too often, referral for psychiatric evaluation is only considered in the context
of a significant worsening of clinical status, such as onset of suicidal ideation,
or when a patient or family is beginning to lose hope and turn to medications
“as a last resort.”
It is important for providers to inform patients and families that waiting for
symptoms to become more severe may decrease the probability of response
or remission of symptoms. (Stroeh and Trivedi 2012)
So, on the one hand they need to be educated to come early for assessment,
and on the other hand, you need to restrict yourself in prescribing medication
unnecessarily or at the drop of hat. 13
REACHING THE UNREACHED IS THE REAL CHALLENGE
Children and adolescents with psychiatric illness in low resource countries is a grossly
under-cared section of population.
By rough estimates, ten percent of children & adolescents have a diagnosable mental
health disorder.
Very few have access to specialist services. The treatment gap is huge.
Service delivery model has to be innovative.
With limited trained child psychiatrists, training other general psychiatrists and even
pediatricians and family physicians may be more important than in high resource
countries.
Sensitization about diagnostic clarity, proper drug selection, some minimal counselling
and psycho-education skills and identifying adverse effects are the minimum targets that
we need to foray into. 14
SELECTIVE AND USEFUL KNOWLEDGE
Transmitting information in this collaborative model has to be specifically very
restricted and simple.
Generalist and other specialist have to be acquainted with restricted number of
medicines.
In case of antipsychotics possible drugs are risperidone, aripiprazole and
quetiapine; in case of antidepressants, fluoxetine, sertraline and escitalopram; in
mood-stabilizers, lithium and divalproex and among drugs for ADHD,
methylphenidate and atomoxetine.
15
CHRONOLOGY OF PROGRESS
In 1997 US Congress authorized FDA to grant additional 6 months of drug exclusivity
in return for conducting specific studies in children.
More recently, introduced legislation has given FDA the authority to require industry
to conduct specific pediatric investigations when off-label use in children can be
anticipated.
‘Best Pharmaceuticals for Children Act’, mandates the final study reports of industry
sponsored trials be posted on the FDA website.
Research Units on Pediatric Psychopharmacology (RUPPs) under the leadership of
NIMH have formed.
Research relevant to child psychopharmacology increased remarkably since then.
(Vitiello 2006)
16
GENERAL PRINCIPLES OF PRESCRIBING FOR CHILDREN
Formulating principles of prescribing psychotropic medicine in childhood and
adolescence is not very simple.
Many a time illness does not fully evolve and diagnosis may be difficult.
Diagnosis can be difficult also because co-morbidity is very common.
Begin with less, go slow and be prepared to end with more. Best way to decide
the dose is mg/kg per day.
This ideally should be child specific data and not the one extrapolated from
adults.
Off-label use has to have a scientific basis, you must take consent and the
rationale for use has to be documented.
17
GENERAL PRINCIPLES OF PRESCRIBING FOR CHILDREN
Regular monitoring of treatment in childhood and adolescence is very
important.
Allow time for an adequate trial of treatment. Where possible, change one
drug at a time.
Monitor outcome in more than one setting like home, school and play
ground.
Education of patient and family; at times, even teacher about medication is
essential.
18
AWARENESS AMONGST TEACHERS ABOUT SIDE EFFECTS OF
MEDICATION
Minor side effects like sedation
Dystonia
Seizure
19
GENERAL PRINCIPLES OF PRESCRIBING FOR CHILDREN
Children need to be studied separately for their own data. Children are not
half, quarter or one-tenth adults.
Simple body weight basis of drug dose fixation is not adequate.
Pharmacodynamics and Pharmacokinetic considerations are important.
Knowledge of essential differences between child and adult psycho-
pharmacology should always guide a prescribing physician.
Long term deleterious effects have to be kept in mind.
20
PHARMACODYNAMICS
Most psychotropics act through neurotransmitters, such as dopamine,
serotonin, and norepinephrine, whose receptors undergo major changes
during development. (Rho & Storey, 2001)
Receptor density tends to peak in preschool years and then gradually declines
towards adult levels in late adolescence. (Chugani et al, 2001)
The impact of these developmental changes on drug activity and possible
implications for efficacy and safety are still not well understood.
However, differences between children and adults in efficacy and safety have
been observed thus suggesting that development can significantly influence
the effects of these medications.
21
PHARMACODYNAMICS
Clearly the developmental stage influences the response to a number of
psychotropic medicines.
Tricyclic antidepressants, though proven effective in adult depression, have
no demonstrable antidepressant effect in children (Hazell et al, 1995)
Amphetamine-like stimulants are more likely to induce euphoria in adults
than in children.
Antipsychotics tend to cause stronger metabolic effects in youth than in
adults (Correll et al, 2009)
Serotonergic antidepressants were found to increase the risk for suicidal
ideation and attempts in children, adolescents, and young adults, but not in
the middle-aged or the elderly.
(Hammad et al, 2006; Stone et al, 2009)
22
PHARMACODYNAMICS
This is evident also in the lower tolerability and efficacy of methylphenidate
in children with ADHD between 3 and 5 years of age as compared with older
children. (Greenhill et al, 2006)
When brain development is abnormal, such as in autism, the effects of
medication can be impacted, as shown by the lack of benefit from selective
serotonin reuptake inhibitors for compulsive and repetitive behaviors in
autism. (King et al, 2009)
Thus, information derived from data from adolescents may not be applicable
to children who are younger or suffer from pervasive disorders of
development.
This underscores the need for research directly in the patient populations
likely to be treated with these medications. (Vitiello B. 2014)
23
PHARMACOKINETICS
Right from absorption to excretion there are many differences between adults and
children and they must be kept in mind while prescribing for children.
24
ABSORPTION:
Although the extent of drug absorption for most medication is similar in
children and adults, the rate of absorption may be faster in children and
peak levels are reached earlier.
Absorption is also dependent on the form in which it is administered i.e.
liquid versus tablet, and levels peak faster for liquid preparations.
(Santosh P.J. 2009)
Ionized drugs (many of them weak acids) may be less well absorbed from
a child’s less acidic stomach. (Taylor E. 2015)
25
METABOLISM:
The normal rate of hepatic metabolism is high in children until the time of
puberty.
The result is that most medications are aggressively metabolized in the liver and
rapidly excreted.
Because what ultimately matters is how much of the drug enters the
bloodstream, treatment of pre-pubertal children may require dose that approach
or equal those for adults.
The use of seemingly high doses for young children may seem counterintuitive to
many parents, and thus it will be helpful for clinicians to explain the role of
increased rate of drug metabolism.
26
METABOLISM:
During the entry into puberty, the rate of hepatic metabolism significantly slows.
For this reason, youngsters who have been on a maintenance dose of psychiatric
medication and tolerating it well may begin to show increasing side effects when
this change in metabolic rate occurs and more of the drug begins to escape the
liver and enter circulation.
Dosage adjustments may then be required, to minimize side effects.
(Preston et al. 2015)
27
DISTRIBUTION:
Children differ from adults in the proportions of extracellular water volume
and body fat.
The proportion of extracellular water decreases substantially from birth
through early adolescence.
Younger children have a relatively larger distribution volume for water-
soluble drugs.
They therefore require a relatively higher dose to achieve a comparable
plasma concentration.
(Johnson M.R. et al 2015)
28
BLOOD - BRAIN BARRIER:
The blood-brain barrier tends to be more permeable in children than in adults.
The greater permeability of the blood-brain barrier in children may mean a
greater than predicted effect.
(Taylor E. 2015)
29
EXCRETION:
The main route of drug elimination is through the kidneys.
Absolute clearance is usually lower in children than in adults, but weight-
adjusted clearance is greater.
Because of the faster elimination, the drug plasma half-life can be shorter
in children than in adults.
A shorter elimination half-life means that plasma steady-state is reached
sooner during repeated administration, and that elimination is faster so
that withdrawal symptoms upon discontinuation are more likely.
In these cases, a more frequent dosing is needed to maintain consistent
therapeutic levels and prevent withdrawal symptoms between doses.
(Vitiello 2014)
30
CLINICAL GUIDELINES
At the starting point, while recommending psychotropic drugs, complexities of
pharmacokinetic and pharmacodynamic factors have to be considered.
Later in every case it is necessary to titrate the dose against the desired clinical
response.
Whenever possible, blood levels should be done.
Some of them are very useful in monitoring the optimum dose of the drugs, e.g.,
lithium and anticonvulsants.
Therapeutic level for :
Lithium 0.6-1.2 mEq/L.
Carbamazepine 8-12 ng/ml
Valproic Acid 50-125 µg/ml.
(Cobert 2013)
31
PREVENTIVE MEASURES TO AVOID DRUG INTERACTION
Obtain a detailed medication history including OTC drugs and compounds from
alternative approaches than modern medicine.
Young patients constitute high risk group.
So, use drugs with minimum interaction potential.
Avoid poly-pharmacy, whenever possible.
Educate patient and family, include written instruction, when appropriate.
Keep detailed, up-dated references on important potential drug interactions.
(Konar 2005)
32
SPECIFIC ISSUES RELATED TO PEDIATRIC PHARMACOLOGY
Let us first discuss diagnosis vs. target symptom approach.
At times, categorical diagnosis is easy to use; at other times, functionally
impairing symptoms control may be a better approach to deal with the
clinical situation.
Effective pharmacotherapists should be mindful of both the target symptoms
and the context and settings in which they occur.
(Bostic & Rho 2006)
33
SPECIFIC ISSUES RELATED TO PEDIATRIC PHARMACOLOGY
Therapeutic alliance is slightly more complicated in children than adults.
In pediatric psychopharmacology specifically, there is always at least a dual
alliance, if not more, that must be acknowledged and nurtured.
Prescribing clinicians should strive to include both patients and parents /
grand parents / guardian into the working alliance paradigms of goal
identification, tasks consolidation, and therapeutic bond establishment.
(Joshi 2006)
34
SPECIFIC ISSUES RELATED TO PEDIATRIC PHARMACOLOGY
Children’s concept about medications is to be acknowledged and respected.
They may be concerned about physical properties of the medication itself like form
or size.
Then there could be wrong kind of notions about medicine. The patient may
believe that only children who are “sick” or “bad” have to take medicine.
Timing of the dose and frequency (like, morning, evening or during school dosage)
have to be kept in mind.
Special caution must be taken in using injectable medications for children and
adolescents with a history of trauma.
(Joshi 2006)
35
SPECIFIC ISSUES RELATED TO PEDIATRIC PHARMACOLOGY
Comorbidity is more a rule than exception in children e.g., Intellectual
Developmental Disorder, Autism, ADHD, ODD, Epilepsy, Conduct Disorder,
Anxiety Disorder, Depression, they all come in different combinations.
Over the last decade, pharmacotherapy in pediatric psychiatry has shown
similar trends toward poly-pharmacy as in adults.
Here you have to be more cautious because children have more propensity
for seizure and EPS.
36
SPECIFIC ISSUES RELATED TO PEDIATRIC PHARMACOLOGY
Adverse events are more likely when multiple drugs are used, and interactions
can be unpredictable.
Combining drugs from the same pharmacological class is rarely indicated,
except when cross-tapering while switching drugs.
Combining drugs can be rational when their pharmacological actions are
complementary, although the side effect burden is usually higher.
37
SPECIFIC ISSUES RELATED TO PEDIATRIC PHARMACOLOGY
Polypharmacy requires pharmacological expertise and should usually be
supervised by a specialist.
When advising investigations, if it is not possible to have an adequate battery
done, be at least optimum.
Adequate investigation may not be feasible due to financial constraints in low
resource countries but important ones cannot be omitted and safety concerns
may never be downplayed.
So taking hints from clinical presentation, regarding adverse effects, may be
more important in the context of low resource countries, when advising
battery of investigation.
38
SOME SPECIAL PRECAUTIONS
First we should be committed to try to diagnose the condition to the best of our
understanding and ability before we prescribe.
We must remember, pharmacotherapy is only a part of treatment plan.
Consideration must be given to all aspect of child’s life like psychosocial,
educational and family interventions.
Obtain an informed consent after discussing possible side effects and need for
monitoring.
Discuss black box warnings.
Use the lowest possible dose.
There should be frequent contact with the patient and the family. After a period
of stabilization (6-12 months), evaluate the need for continued medications.39
CONCLUSION
There is great concern today that children are being over treated with
medication, especially in the US. (Rapoport 2013)
By contrast, many countries make so little use of medication that it
seems probable that children who could benefit do not receive it.
Under-treatment is perhaps a bigger problem globally than
overmedication.
With limited availability of professionals, the low resource countries
should focus on services delivery to reach to the widest population.
40
FIVE SIMPLE QUESTIONS IN RELATION TO CHILD
AND ADOLESCENT PSYCHOPHARMACOLOGY
1. As compared to adult, liver is:
A. More Active
B. Less Active
2. As compered to adult, elimination (weight adjusted clearance) through kidneys is:
A. Faster
B. Slower
3. Research Unit of Pediatric Psychopharmacology (RUPP) has been formed under leadership of:
A. Royal College of Psychiatrist, London
B. National Institute of Mental Health
C. United States Food and Drug Administration
4. Blood brain barrier in children is:
A. Less permeable
B. More permeable
5. As compared to adult, metabolic side effects of antipsychotics are:
A. More common
B. Less common
41
BEFORE WORKSHOP AFTER WORKSHOP
ANSWER SHEET
1. As compared to adult, liver is:
A. More Active
B. Less Active
2. As compered to adult, elimination (weight adjusted clearance) through kidneys is:
A. Faster
B. Slower
3. Research Unit of Pediatric Psychopharmacology (RUPP) has been formed under leadership of:
A. Royal College of Psychiatrist, London
B. National Institute of Mental Health
C. United States Food and Drug Administration
4. Blood brain barrier in children is:
A. Less permeable
B. More permeable
5. As compared to adult, metabolic side effects of antipsychotics are:
A. More common
B. Less common
42





THANK43

Más contenido relacionado

La actualidad más candente

Adhd and the_brain
Adhd and the_brainAdhd and the_brain
Adhd and the_brainCMoondog
 
Adhd treatment updates
Adhd treatment updatesAdhd treatment updates
Adhd treatment updatesYasir Hameed
 
Adhd webinar wolraich
Adhd webinar wolraichAdhd webinar wolraich
Adhd webinar wolraichAmir Mahmoud
 
Attention Deficit Disorder with Hyperactivity (ADHD)
Attention Deficit Disorder with Hyperactivity (ADHD)Attention Deficit Disorder with Hyperactivity (ADHD)
Attention Deficit Disorder with Hyperactivity (ADHD)ishamagar
 
Pediatric Pharm--against
Pediatric Pharm--againstPediatric Pharm--against
Pediatric Pharm--againstpsych493
 
Treatment Programs HARPS Program (Helping At-Risk Pregnant Women Succeed) - C...
Treatment Programs HARPS Program (Helping At-Risk Pregnant Women Succeed) - C...Treatment Programs HARPS Program (Helping At-Risk Pregnant Women Succeed) - C...
Treatment Programs HARPS Program (Helping At-Risk Pregnant Women Succeed) - C...ErikaAGoyer
 
ADHD in adult: advances in pharmacological interventions
ADHD in adult: advances in pharmacological interventionsADHD in adult: advances in pharmacological interventions
ADHD in adult: advances in pharmacological interventionsYasir Hameed
 
Fac 4-chronis-tuscano
Fac 4-chronis-tuscanoFac 4-chronis-tuscano
Fac 4-chronis-tuscanoAmir Mahmoud
 
Pregnancy & Addiction 2011 - Revision 2
Pregnancy & Addiction 2011 - Revision 2Pregnancy & Addiction 2011 - Revision 2
Pregnancy & Addiction 2011 - Revision 2Stacy Seikel
 
Pharmaceutical performance enhancement for children with adhd
Pharmaceutical performance enhancement for children with adhdPharmaceutical performance enhancement for children with adhd
Pharmaceutical performance enhancement for children with adhdMollieMcGee1
 
Neurobehavioral Disorder Associated with Prenatal Alcohol Exposure (ND-PAE): ...
Neurobehavioral Disorder Associated with Prenatal Alcohol Exposure (ND-PAE): ...Neurobehavioral Disorder Associated with Prenatal Alcohol Exposure (ND-PAE): ...
Neurobehavioral Disorder Associated with Prenatal Alcohol Exposure (ND-PAE): ...BARRY STANLEY 2 fasd
 
Addiction In Pregnancy Ver.2
Addiction In Pregnancy Ver.2Addiction In Pregnancy Ver.2
Addiction In Pregnancy Ver.2James Nocon
 
Brain developm adhd2
Brain developm adhd2Brain developm adhd2
Brain developm adhd2Madhu Sudan
 
Safety Considerations in the use of Psychotropic Medication in Children and T...
Safety Considerations in the use of Psychotropic Medication in Children and T...Safety Considerations in the use of Psychotropic Medication in Children and T...
Safety Considerations in the use of Psychotropic Medication in Children and T...Stephen Grcevich, MD
 
DSM-V Criteria for ADHD
DSM-V Criteria for ADHDDSM-V Criteria for ADHD
DSM-V Criteria for ADHDDr. Paul Ebben
 

La actualidad más candente (20)

Adhd and the_brain
Adhd and the_brainAdhd and the_brain
Adhd and the_brain
 
Adhd treatment updates
Adhd treatment updatesAdhd treatment updates
Adhd treatment updates
 
Adhd webinar wolraich
Adhd webinar wolraichAdhd webinar wolraich
Adhd webinar wolraich
 
Attention Deficit Disorder with Hyperactivity (ADHD)
Attention Deficit Disorder with Hyperactivity (ADHD)Attention Deficit Disorder with Hyperactivity (ADHD)
Attention Deficit Disorder with Hyperactivity (ADHD)
 
Pediatric Pharm--against
Pediatric Pharm--againstPediatric Pharm--against
Pediatric Pharm--against
 
Treatment Programs HARPS Program (Helping At-Risk Pregnant Women Succeed) - C...
Treatment Programs HARPS Program (Helping At-Risk Pregnant Women Succeed) - C...Treatment Programs HARPS Program (Helping At-Risk Pregnant Women Succeed) - C...
Treatment Programs HARPS Program (Helping At-Risk Pregnant Women Succeed) - C...
 
ADHD in adult: advances in pharmacological interventions
ADHD in adult: advances in pharmacological interventionsADHD in adult: advances in pharmacological interventions
ADHD in adult: advances in pharmacological interventions
 
Fac 4-chronis-tuscano
Fac 4-chronis-tuscanoFac 4-chronis-tuscano
Fac 4-chronis-tuscano
 
Michael Guyton, M.D. ADHD Whirlwind
Michael Guyton, M.D. ADHD Whirlwind Michael Guyton, M.D. ADHD Whirlwind
Michael Guyton, M.D. ADHD Whirlwind
 
Pregnancy & Addiction 2011 - Revision 2
Pregnancy & Addiction 2011 - Revision 2Pregnancy & Addiction 2011 - Revision 2
Pregnancy & Addiction 2011 - Revision 2
 
NIDA-Addiction
NIDA-AddictionNIDA-Addiction
NIDA-Addiction
 
Attention-Deficity Hyperactivity Disorder
Attention-Deficity Hyperactivity DisorderAttention-Deficity Hyperactivity Disorder
Attention-Deficity Hyperactivity Disorder
 
Pharmaceutical performance enhancement for children with adhd
Pharmaceutical performance enhancement for children with adhdPharmaceutical performance enhancement for children with adhd
Pharmaceutical performance enhancement for children with adhd
 
Fyre poster:display
Fyre poster:displayFyre poster:display
Fyre poster:display
 
Neurobehavioral Disorder Associated with Prenatal Alcohol Exposure (ND-PAE): ...
Neurobehavioral Disorder Associated with Prenatal Alcohol Exposure (ND-PAE): ...Neurobehavioral Disorder Associated with Prenatal Alcohol Exposure (ND-PAE): ...
Neurobehavioral Disorder Associated with Prenatal Alcohol Exposure (ND-PAE): ...
 
Teen Drug Testing Ebook
Teen Drug Testing EbookTeen Drug Testing Ebook
Teen Drug Testing Ebook
 
Addiction In Pregnancy Ver.2
Addiction In Pregnancy Ver.2Addiction In Pregnancy Ver.2
Addiction In Pregnancy Ver.2
 
Brain developm adhd2
Brain developm adhd2Brain developm adhd2
Brain developm adhd2
 
Safety Considerations in the use of Psychotropic Medication in Children and T...
Safety Considerations in the use of Psychotropic Medication in Children and T...Safety Considerations in the use of Psychotropic Medication in Children and T...
Safety Considerations in the use of Psychotropic Medication in Children and T...
 
DSM-V Criteria for ADHD
DSM-V Criteria for ADHDDSM-V Criteria for ADHD
DSM-V Criteria for ADHD
 

Destacado

Differentiating Intellectual Disability, Autism Spectrum Disorder, & Specific...
Differentiating Intellectual Disability, Autism Spectrum Disorder, & Specific...Differentiating Intellectual Disability, Autism Spectrum Disorder, & Specific...
Differentiating Intellectual Disability, Autism Spectrum Disorder, & Specific...Consulting Psychologists
 
Workshop on child and adolescent psychopharmacology
Workshop on child and adolescent psychopharmacologyWorkshop on child and adolescent psychopharmacology
Workshop on child and adolescent psychopharmacologyDevashish Konar
 
Pediatric Psychopharmacology
Pediatric PsychopharmacologyPediatric Psychopharmacology
Pediatric PsychopharmacologyPallav Pareek
 
Depression In Children: Behavioral Manifestations and Intervention
Depression In Children: Behavioral Manifestations and InterventionDepression In Children: Behavioral Manifestations and Intervention
Depression In Children: Behavioral Manifestations and InterventionDavid Songco
 
The adhd brain
The adhd brainThe adhd brain
The adhd brainCMoondog
 
Children,Teens and,Depression
Children,Teens and,DepressionChildren,Teens and,Depression
Children,Teens and,Depressionnatalie S
 
Basic psychopharmacology for children and adolescents revised (1)
Basic psychopharmacology for children and adolescents revised (1)Basic psychopharmacology for children and adolescents revised (1)
Basic psychopharmacology for children and adolescents revised (1)decaturfamilypsychiatry
 
Children and depression_ppt
Children and depression_pptChildren and depression_ppt
Children and depression_pptCMoondog
 
Current Management of Depression and Anxiety in Children and Adolescents
Current Management of Depression and Anxiety in Children and AdolescentsCurrent Management of Depression and Anxiety in Children and Adolescents
Current Management of Depression and Anxiety in Children and AdolescentsStephen Grcevich, MD
 
Understanding Learning Disability
Understanding Learning Disability Understanding Learning Disability
Understanding Learning Disability Simon Muir
 
Child schizophrenia and depression
Child schizophrenia and depressionChild schizophrenia and depression
Child schizophrenia and depressionNimmy Tomy
 
ADHD powerpoint
ADHD powerpointADHD powerpoint
ADHD powerpointmicalg
 
Keeping Up To Date With The Literature In Child Health
Keeping Up To Date With The Literature In Child HealthKeeping Up To Date With The Literature In Child Health
Keeping Up To Date With The Literature In Child Healthcscoville
 

Destacado (18)

Differentiating Intellectual Disability, Autism Spectrum Disorder, & Specific...
Differentiating Intellectual Disability, Autism Spectrum Disorder, & Specific...Differentiating Intellectual Disability, Autism Spectrum Disorder, & Specific...
Differentiating Intellectual Disability, Autism Spectrum Disorder, & Specific...
 
Workshop on child and adolescent psychopharmacology
Workshop on child and adolescent psychopharmacologyWorkshop on child and adolescent psychopharmacology
Workshop on child and adolescent psychopharmacology
 
Pediatric Psychopharmacology
Pediatric PsychopharmacologyPediatric Psychopharmacology
Pediatric Psychopharmacology
 
Adhd
AdhdAdhd
Adhd
 
Depression In Children: Behavioral Manifestations and Intervention
Depression In Children: Behavioral Manifestations and InterventionDepression In Children: Behavioral Manifestations and Intervention
Depression In Children: Behavioral Manifestations and Intervention
 
The adhd brain
The adhd brainThe adhd brain
The adhd brain
 
Children,Teens and,Depression
Children,Teens and,DepressionChildren,Teens and,Depression
Children,Teens and,Depression
 
Basic psychopharmacology for children and adolescents revised (1)
Basic psychopharmacology for children and adolescents revised (1)Basic psychopharmacology for children and adolescents revised (1)
Basic psychopharmacology for children and adolescents revised (1)
 
Children and depression_ppt
Children and depression_pptChildren and depression_ppt
Children and depression_ppt
 
Current Management of Depression and Anxiety in Children and Adolescents
Current Management of Depression and Anxiety in Children and AdolescentsCurrent Management of Depression and Anxiety in Children and Adolescents
Current Management of Depression and Anxiety in Children and Adolescents
 
Understanding Learning Disability
Understanding Learning Disability Understanding Learning Disability
Understanding Learning Disability
 
Child schizophrenia and depression
Child schizophrenia and depressionChild schizophrenia and depression
Child schizophrenia and depression
 
ADHD powerpoint
ADHD powerpointADHD powerpoint
ADHD powerpoint
 
Child psychiatry
Child psychiatryChild psychiatry
Child psychiatry
 
LEARNING DISABILITY
LEARNING DISABILITYLEARNING DISABILITY
LEARNING DISABILITY
 
Keeping Up To Date With The Literature In Child Health
Keeping Up To Date With The Literature In Child HealthKeeping Up To Date With The Literature In Child Health
Keeping Up To Date With The Literature In Child Health
 
ADHD Bipolar Disorder
ADHD Bipolar DisorderADHD Bipolar Disorder
ADHD Bipolar Disorder
 
Understanding ADHD
Understanding ADHDUnderstanding ADHD
Understanding ADHD
 

Similar a Iacapap workshop on PRESCRIBING FOR CHILDREN AND ADOLESCENTS: PERSPECTIVE FROM LOW RESOURCE COUNTRY

PediatricAntipsychoticsSparksDuncan
PediatricAntipsychoticsSparksDuncanPediatricAntipsychoticsSparksDuncan
PediatricAntipsychoticsSparksDuncanBarry Duncan
 
Proposal.docx
Proposal.docxProposal.docx
Proposal.docxwrite22
 
PRESCRIBING FOR CHILDREN AND ADOLESCENTS.docx
PRESCRIBING FOR CHILDREN AND ADOLESCENTS.docxPRESCRIBING FOR CHILDREN AND ADOLESCENTS.docx
PRESCRIBING FOR CHILDREN AND ADOLESCENTS.docxwrite4
 
Over-Diagnosis of Pediatric ADHD
Over-Diagnosis of Pediatric ADHDOver-Diagnosis of Pediatric ADHD
Over-Diagnosis of Pediatric ADHDAlexandraPerkins5
 
Attention Deficit Hyperactivity Disorder (ADHD) In Children Rationale For It...
Attention Deficit Hyperactivity Disorder (ADHD) In Children  Rationale For It...Attention Deficit Hyperactivity Disorder (ADHD) In Children  Rationale For It...
Attention Deficit Hyperactivity Disorder (ADHD) In Children Rationale For It...Erica Thompson
 
Essay On Drawbacks And Benefits To Diagnosing...
Essay On Drawbacks And Benefits To Diagnosing...Essay On Drawbacks And Benefits To Diagnosing...
Essay On Drawbacks And Benefits To Diagnosing...Anna Melek
 
Pediatric Bipolar (against)
Pediatric Bipolar (against)Pediatric Bipolar (against)
Pediatric Bipolar (against)psych493
 
Attention Deficit Hyperactivity Disorder Essay
Attention Deficit Hyperactivity Disorder EssayAttention Deficit Hyperactivity Disorder Essay
Attention Deficit Hyperactivity Disorder EssayKrystal Green
 
A Brief Note On Pain And Prescription Drugs Essay
A Brief Note On Pain And Prescription Drugs EssayA Brief Note On Pain And Prescription Drugs Essay
A Brief Note On Pain And Prescription Drugs EssayJennifer Campbell
 
Au psy492 m7_a2_pp_cooper_l
Au psy492 m7_a2_pp_cooper_lAu psy492 m7_a2_pp_cooper_l
Au psy492 m7_a2_pp_cooper_lLaToyaCooper
 
The utility of psychotropic drugs on patients with fetal alcohol spectrum dis...
The utility of psychotropic drugs on patients with fetal alcohol spectrum dis...The utility of psychotropic drugs on patients with fetal alcohol spectrum dis...
The utility of psychotropic drugs on patients with fetal alcohol spectrum dis...BARRY STANLEY 2 fasd
 
Assigned Disruptive Mood Dysregulation Disorder Psychotropic drugs are common...
Assigned Disruptive Mood Dysregulation Disorder Psychotropic drugs are common...Assigned Disruptive Mood Dysregulation Disorder Psychotropic drugs are common...
Assigned Disruptive Mood Dysregulation Disorder Psychotropic drugs are common...write4
 
Assigned Disruptive Mood Dysregulation Disorder Psychotropic drugs are common...
Assigned Disruptive Mood Dysregulation Disorder Psychotropic drugs are common...Assigned Disruptive Mood Dysregulation Disorder Psychotropic drugs are common...
Assigned Disruptive Mood Dysregulation Disorder Psychotropic drugs are common...write22
 
STRIKE THE RIGHT BALANCE WHILE PRESCRIBING PSYCHOTROPICS TO CHILDREN IN DEVEL...
STRIKE THE RIGHT BALANCE WHILE PRESCRIBING PSYCHOTROPICS TO CHILDREN IN DEVEL...STRIKE THE RIGHT BALANCE WHILE PRESCRIBING PSYCHOTROPICS TO CHILDREN IN DEVEL...
STRIKE THE RIGHT BALANCE WHILE PRESCRIBING PSYCHOTROPICS TO CHILDREN IN DEVEL...Devashish Konar
 

Similar a Iacapap workshop on PRESCRIBING FOR CHILDREN AND ADOLESCENTS: PERSPECTIVE FROM LOW RESOURCE COUNTRY (20)

PediatricAntipsychoticsSparksDuncan
PediatricAntipsychoticsSparksDuncanPediatricAntipsychoticsSparksDuncan
PediatricAntipsychoticsSparksDuncan
 
The Colt Of A Booklet
The Colt Of A BookletThe Colt Of A Booklet
The Colt Of A Booklet
 
The Colt Of A Booklet
The Colt Of A BookletThe Colt Of A Booklet
The Colt Of A Booklet
 
Proposal.docx
Proposal.docxProposal.docx
Proposal.docx
 
PRESCRIBING FOR CHILDREN AND ADOLESCENTS.docx
PRESCRIBING FOR CHILDREN AND ADOLESCENTS.docxPRESCRIBING FOR CHILDREN AND ADOLESCENTS.docx
PRESCRIBING FOR CHILDREN AND ADOLESCENTS.docx
 
Over-Diagnosis of Pediatric ADHD
Over-Diagnosis of Pediatric ADHDOver-Diagnosis of Pediatric ADHD
Over-Diagnosis of Pediatric ADHD
 
Attention Deficit Hyperactivity Disorder (ADHD) In Children Rationale For It...
Attention Deficit Hyperactivity Disorder (ADHD) In Children  Rationale For It...Attention Deficit Hyperactivity Disorder (ADHD) In Children  Rationale For It...
Attention Deficit Hyperactivity Disorder (ADHD) In Children Rationale For It...
 
Essay On Drawbacks And Benefits To Diagnosing...
Essay On Drawbacks And Benefits To Diagnosing...Essay On Drawbacks And Benefits To Diagnosing...
Essay On Drawbacks And Benefits To Diagnosing...
 
paediatrics
paediatricspaediatrics
paediatrics
 
Pediatric Bipolar (against)
Pediatric Bipolar (against)Pediatric Bipolar (against)
Pediatric Bipolar (against)
 
Attention Deficit Hyperactivity Disorder Essay
Attention Deficit Hyperactivity Disorder EssayAttention Deficit Hyperactivity Disorder Essay
Attention Deficit Hyperactivity Disorder Essay
 
A Brief Note On Pain And Prescription Drugs Essay
A Brief Note On Pain And Prescription Drugs EssayA Brief Note On Pain And Prescription Drugs Essay
A Brief Note On Pain And Prescription Drugs Essay
 
Au psy492 m7_a2_pp_cooper_l
Au psy492 m7_a2_pp_cooper_lAu psy492 m7_a2_pp_cooper_l
Au psy492 m7_a2_pp_cooper_l
 
The utility of psychotropic drugs on patients with fetal alcohol spectrum dis...
The utility of psychotropic drugs on patients with fetal alcohol spectrum dis...The utility of psychotropic drugs on patients with fetal alcohol spectrum dis...
The utility of psychotropic drugs on patients with fetal alcohol spectrum dis...
 
Clarity
ClarityClarity
Clarity
 
Assigned Disruptive Mood Dysregulation Disorder Psychotropic drugs are common...
Assigned Disruptive Mood Dysregulation Disorder Psychotropic drugs are common...Assigned Disruptive Mood Dysregulation Disorder Psychotropic drugs are common...
Assigned Disruptive Mood Dysregulation Disorder Psychotropic drugs are common...
 
Assigned Disruptive Mood Dysregulation Disorder Psychotropic drugs are common...
Assigned Disruptive Mood Dysregulation Disorder Psychotropic drugs are common...Assigned Disruptive Mood Dysregulation Disorder Psychotropic drugs are common...
Assigned Disruptive Mood Dysregulation Disorder Psychotropic drugs are common...
 
TBRI Thesis
TBRI ThesisTBRI Thesis
TBRI Thesis
 
STRIKE THE RIGHT BALANCE WHILE PRESCRIBING PSYCHOTROPICS TO CHILDREN IN DEVEL...
STRIKE THE RIGHT BALANCE WHILE PRESCRIBING PSYCHOTROPICS TO CHILDREN IN DEVEL...STRIKE THE RIGHT BALANCE WHILE PRESCRIBING PSYCHOTROPICS TO CHILDREN IN DEVEL...
STRIKE THE RIGHT BALANCE WHILE PRESCRIBING PSYCHOTROPICS TO CHILDREN IN DEVEL...
 
psychotropic medication use in foster care youth
psychotropic medication use in foster care youth psychotropic medication use in foster care youth
psychotropic medication use in foster care youth
 

Más de Devashish Konar

Biopsychosocial Model in Psychiatry- Revisited.pptx
Biopsychosocial Model in Psychiatry- Revisited.pptxBiopsychosocial Model in Psychiatry- Revisited.pptx
Biopsychosocial Model in Psychiatry- Revisited.pptxDevashish Konar
 
Preventive psychiatry in india: Preventing on Child Psychiatric Front
Preventive psychiatry in india: Preventing on Child Psychiatric FrontPreventive psychiatry in india: Preventing on Child Psychiatric Front
Preventive psychiatry in india: Preventing on Child Psychiatric FrontDevashish Konar
 
Road map for social psychiatry in 21 st centrury role of industry -
Road map for social psychiatry in 21 st centrury  role of industry -Road map for social psychiatry in 21 st centrury  role of industry -
Road map for social psychiatry in 21 st centrury role of industry -Devashish Konar
 
Regeneration of mind and brain
Regeneration of mind and brainRegeneration of mind and brain
Regeneration of mind and brainDevashish Konar
 
Executive dysfuntion in ADHD
Executive dysfuntion in ADHDExecutive dysfuntion in ADHD
Executive dysfuntion in ADHDDevashish Konar
 
Neurobiological understanding of anxiety disorder
Neurobiological understanding of anxiety disorder  Neurobiological understanding of anxiety disorder
Neurobiological understanding of anxiety disorder Devashish Konar
 
Volume neurotransmission
Volume neurotransmissionVolume neurotransmission
Volume neurotransmissionDevashish Konar
 
Tricks of managing bipolar disorder
Tricks of managing bipolar disorderTricks of managing bipolar disorder
Tricks of managing bipolar disorderDevashish Konar
 
Same sex relations the journey over time
Same sex relations the journey over timeSame sex relations the journey over time
Same sex relations the journey over timeDevashish Konar
 
POSITIVE PARENTING : PERSPECTIVES AND PRINCIPLES OF PARENTING WITH INDIAN EMP...
POSITIVE PARENTING : PERSPECTIVES AND PRINCIPLES OF PARENTING WITH INDIAN EMP...POSITIVE PARENTING : PERSPECTIVES AND PRINCIPLES OF PARENTING WITH INDIAN EMP...
POSITIVE PARENTING : PERSPECTIVES AND PRINCIPLES OF PARENTING WITH INDIAN EMP...Devashish Konar
 
Evolution of human brain & mind
Evolution of human brain & mindEvolution of human brain & mind
Evolution of human brain & mindDevashish Konar
 
Existentialism as a philosophical framework for practicing psychiatry
Existentialism as a philosophical framework for practicing psychiatryExistentialism as a philosophical framework for practicing psychiatry
Existentialism as a philosophical framework for practicing psychiatryDevashish Konar
 
Be an advocate of children
Be an advocate of childrenBe an advocate of children
Be an advocate of childrenDevashish Konar
 

Más de Devashish Konar (15)

Biopsychosocial Model in Psychiatry- Revisited.pptx
Biopsychosocial Model in Psychiatry- Revisited.pptxBiopsychosocial Model in Psychiatry- Revisited.pptx
Biopsychosocial Model in Psychiatry- Revisited.pptx
 
Preventive psychiatry in india: Preventing on Child Psychiatric Front
Preventive psychiatry in india: Preventing on Child Psychiatric FrontPreventive psychiatry in india: Preventing on Child Psychiatric Front
Preventive psychiatry in india: Preventing on Child Psychiatric Front
 
Road map for social psychiatry in 21 st centrury role of industry -
Road map for social psychiatry in 21 st centrury  role of industry -Road map for social psychiatry in 21 st centrury  role of industry -
Road map for social psychiatry in 21 st centrury role of industry -
 
Regeneration of mind and brain
Regeneration of mind and brainRegeneration of mind and brain
Regeneration of mind and brain
 
Executive dysfuntion in ADHD
Executive dysfuntion in ADHDExecutive dysfuntion in ADHD
Executive dysfuntion in ADHD
 
Neurobiological understanding of anxiety disorder
Neurobiological understanding of anxiety disorder  Neurobiological understanding of anxiety disorder
Neurobiological understanding of anxiety disorder
 
Volume neurotransmission
Volume neurotransmissionVolume neurotransmission
Volume neurotransmission
 
Tricks of managing bipolar disorder
Tricks of managing bipolar disorderTricks of managing bipolar disorder
Tricks of managing bipolar disorder
 
Same sex relations the journey over time
Same sex relations the journey over timeSame sex relations the journey over time
Same sex relations the journey over time
 
POSITIVE PARENTING : PERSPECTIVES AND PRINCIPLES OF PARENTING WITH INDIAN EMP...
POSITIVE PARENTING : PERSPECTIVES AND PRINCIPLES OF PARENTING WITH INDIAN EMP...POSITIVE PARENTING : PERSPECTIVES AND PRINCIPLES OF PARENTING WITH INDIAN EMP...
POSITIVE PARENTING : PERSPECTIVES AND PRINCIPLES OF PARENTING WITH INDIAN EMP...
 
Evolution of human brain & mind
Evolution of human brain & mindEvolution of human brain & mind
Evolution of human brain & mind
 
Existentialism as a philosophical framework for practicing psychiatry
Existentialism as a philosophical framework for practicing psychiatryExistentialism as a philosophical framework for practicing psychiatry
Existentialism as a philosophical framework for practicing psychiatry
 
Be an advocate of children
Be an advocate of childrenBe an advocate of children
Be an advocate of children
 
Landscape of psychiatry
Landscape of psychiatryLandscape of psychiatry
Landscape of psychiatry
 
Parenting
ParentingParenting
Parenting
 

Último

SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 

Último (20)

SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 

Iacapap workshop on PRESCRIBING FOR CHILDREN AND ADOLESCENTS: PERSPECTIVE FROM LOW RESOURCE COUNTRY

  • 1. WORKSHOP ON PRESCRIBING FOR CHILDREN AND ADOLESCENTS: PERSPECTIVE FROM LOW RESOURCE COUNTRY Devashish Konar Consultant Psychiatrist & Director Mental Health Care Centre, Kolkata & Burdwan, India 120 September 2016, Calgary
  • 2. LEARNING OBJECTIVES: • Stimulating people to find ways to cater treatment in low resource countries. • In countries where Child Psychiatrists are scarce, simplifying basic concepts of paediatric psychopharmacology to educate other professionals, who need to be involved in the treatment of unreached psychologically ill children. 2
  • 3. FIVE SIMPLE QUESTIONS IN RELATION TO CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY 1. As compared to adult, liver is: A. More Active B. Less Active 2. As compered to adult, elimination (weight adjusted clearance) through kidneys is: A. Faster B. Slower 3. Research Unit of Pediatric Psychopharmacology (RUPP) has been formed under leadership of: A. Royal College of Psychiatrist, London B. National Institute of Mental Health C. United States Food and Drug Administration 4. Blood brain barrier in children is: A. Less permeable B. More permeable 5. As compared to adult, metabolic side effects of antipsychotics are: A. More common B. Less common 3 BEFORE WORKSHOP AFTER WORKSHOP
  • 4. ECONOMIC CLASSIFICATIONS OF COUNTRIES OF THE WORLD: •High resource •Low resource Developed Developing Underdeveloped 4 First World Second World Third World Country TWO DISTINCT WORLDS
  • 5. HIGH RESOURCE Where there are many child psychiatrists, and a team working with the children. Burning issue  5 Are we prescribing more?
  • 6. LOW RESOURCE Where there are very few child psychiatrists, and there is hardly any team working with children. Burning Issue  6 Are we able to reach children who need treatment?
  • 7. ??? TEAM WORK ??? IN LOW RESOURCE COUNTRIES Do we need team work? Is it the same team we are talking about as in high resource countries? Whom to educate? What to educate? How to make a team? 7
  • 8. CASE VIGNETTE A child of 13 years sleeping excessively, yawning when awake, nagging, clinging, irritable, demanding & destructive. Illness started following a brief febrile illness. Earlier had similar episode 8 months back. What would you specifically want to know about this case? - History of bipolarity in the family - Thyroid status - Psychosocial stressor (+) (-) 8 (-)
  • 9. HOW DO YOU MANAGE? Take proper history Psycho-education about bipolarity Start treatment in a way that mania is not precipitated All medicines to be built up slow Frequent follow up visits Support yourself with investigation related to treatment Plan prolonged follow-up 9
  • 10. FEW DRUGS LICENSED Historically, pediatric pharmacology in general and pediatric psychopharmacology in particular have received much less research interest and funding than their adult counterparts. As a consequence, relatively few drugs are licensed for use in child and adolescent populations. (Coghill & Sinita 2014) There is growing evidence base of increasingly widespread practice of using psychopharmacological treatment in children and adolescents. (Huline-Dickens 2014) 10
  • 11. CHILDHOOD PSYCHIATRIC ILLNESSES ARE NOT TRIVIAL ONES Childhood and adolescence is a period of extraordinary biological, psychological and social growth. However, at such times, individuals are also vulnerable to disruptions of healthy development. In fact, a staggering 50% of all adult psychiatric disorders have manifested by age 14, with 75% manifesting by age 24. Moreover, two thirds of pediatric-onset psychiatric disorders are moderate or severe, and most continue into adulthood. Such pattern clearly indicate the importance of identifying and appropriately treating psychiatric disorders as early as possible to preserve healthy development and to reduce individual suffering and societal burden. (Correll et al 2013) 11
  • 12. SHIFT TO COLLABORATIVE CARE Mental health issues are being recognized more and more at an earlier age. Issue is alarming, at the same time recognizing them early is good for the child. The shortage of clinicians with specialized training is always the main constraint in case of low resource countries. Medication may become important part of treatment. Judicious evidence based prescribing, slow titration and never, ever, over-prescribing, should be the mantra to succeed in treating children. Medication is only one piece of treatment plan, but relying on it may be in need if other trained personnel are not available. 12
  • 13. CONSULTATION SHOULD BE EARLY, TREATMENT JUDICIOUS One of the most important need in case of child mental health is facilitation of earlier psychiatric consultation. Too often, referral for psychiatric evaluation is only considered in the context of a significant worsening of clinical status, such as onset of suicidal ideation, or when a patient or family is beginning to lose hope and turn to medications “as a last resort.” It is important for providers to inform patients and families that waiting for symptoms to become more severe may decrease the probability of response or remission of symptoms. (Stroeh and Trivedi 2012) So, on the one hand they need to be educated to come early for assessment, and on the other hand, you need to restrict yourself in prescribing medication unnecessarily or at the drop of hat. 13
  • 14. REACHING THE UNREACHED IS THE REAL CHALLENGE Children and adolescents with psychiatric illness in low resource countries is a grossly under-cared section of population. By rough estimates, ten percent of children & adolescents have a diagnosable mental health disorder. Very few have access to specialist services. The treatment gap is huge. Service delivery model has to be innovative. With limited trained child psychiatrists, training other general psychiatrists and even pediatricians and family physicians may be more important than in high resource countries. Sensitization about diagnostic clarity, proper drug selection, some minimal counselling and psycho-education skills and identifying adverse effects are the minimum targets that we need to foray into. 14
  • 15. SELECTIVE AND USEFUL KNOWLEDGE Transmitting information in this collaborative model has to be specifically very restricted and simple. Generalist and other specialist have to be acquainted with restricted number of medicines. In case of antipsychotics possible drugs are risperidone, aripiprazole and quetiapine; in case of antidepressants, fluoxetine, sertraline and escitalopram; in mood-stabilizers, lithium and divalproex and among drugs for ADHD, methylphenidate and atomoxetine. 15
  • 16. CHRONOLOGY OF PROGRESS In 1997 US Congress authorized FDA to grant additional 6 months of drug exclusivity in return for conducting specific studies in children. More recently, introduced legislation has given FDA the authority to require industry to conduct specific pediatric investigations when off-label use in children can be anticipated. ‘Best Pharmaceuticals for Children Act’, mandates the final study reports of industry sponsored trials be posted on the FDA website. Research Units on Pediatric Psychopharmacology (RUPPs) under the leadership of NIMH have formed. Research relevant to child psychopharmacology increased remarkably since then. (Vitiello 2006) 16
  • 17. GENERAL PRINCIPLES OF PRESCRIBING FOR CHILDREN Formulating principles of prescribing psychotropic medicine in childhood and adolescence is not very simple. Many a time illness does not fully evolve and diagnosis may be difficult. Diagnosis can be difficult also because co-morbidity is very common. Begin with less, go slow and be prepared to end with more. Best way to decide the dose is mg/kg per day. This ideally should be child specific data and not the one extrapolated from adults. Off-label use has to have a scientific basis, you must take consent and the rationale for use has to be documented. 17
  • 18. GENERAL PRINCIPLES OF PRESCRIBING FOR CHILDREN Regular monitoring of treatment in childhood and adolescence is very important. Allow time for an adequate trial of treatment. Where possible, change one drug at a time. Monitor outcome in more than one setting like home, school and play ground. Education of patient and family; at times, even teacher about medication is essential. 18
  • 19. AWARENESS AMONGST TEACHERS ABOUT SIDE EFFECTS OF MEDICATION Minor side effects like sedation Dystonia Seizure 19
  • 20. GENERAL PRINCIPLES OF PRESCRIBING FOR CHILDREN Children need to be studied separately for their own data. Children are not half, quarter or one-tenth adults. Simple body weight basis of drug dose fixation is not adequate. Pharmacodynamics and Pharmacokinetic considerations are important. Knowledge of essential differences between child and adult psycho- pharmacology should always guide a prescribing physician. Long term deleterious effects have to be kept in mind. 20
  • 21. PHARMACODYNAMICS Most psychotropics act through neurotransmitters, such as dopamine, serotonin, and norepinephrine, whose receptors undergo major changes during development. (Rho & Storey, 2001) Receptor density tends to peak in preschool years and then gradually declines towards adult levels in late adolescence. (Chugani et al, 2001) The impact of these developmental changes on drug activity and possible implications for efficacy and safety are still not well understood. However, differences between children and adults in efficacy and safety have been observed thus suggesting that development can significantly influence the effects of these medications. 21
  • 22. PHARMACODYNAMICS Clearly the developmental stage influences the response to a number of psychotropic medicines. Tricyclic antidepressants, though proven effective in adult depression, have no demonstrable antidepressant effect in children (Hazell et al, 1995) Amphetamine-like stimulants are more likely to induce euphoria in adults than in children. Antipsychotics tend to cause stronger metabolic effects in youth than in adults (Correll et al, 2009) Serotonergic antidepressants were found to increase the risk for suicidal ideation and attempts in children, adolescents, and young adults, but not in the middle-aged or the elderly. (Hammad et al, 2006; Stone et al, 2009) 22
  • 23. PHARMACODYNAMICS This is evident also in the lower tolerability and efficacy of methylphenidate in children with ADHD between 3 and 5 years of age as compared with older children. (Greenhill et al, 2006) When brain development is abnormal, such as in autism, the effects of medication can be impacted, as shown by the lack of benefit from selective serotonin reuptake inhibitors for compulsive and repetitive behaviors in autism. (King et al, 2009) Thus, information derived from data from adolescents may not be applicable to children who are younger or suffer from pervasive disorders of development. This underscores the need for research directly in the patient populations likely to be treated with these medications. (Vitiello B. 2014) 23
  • 24. PHARMACOKINETICS Right from absorption to excretion there are many differences between adults and children and they must be kept in mind while prescribing for children. 24
  • 25. ABSORPTION: Although the extent of drug absorption for most medication is similar in children and adults, the rate of absorption may be faster in children and peak levels are reached earlier. Absorption is also dependent on the form in which it is administered i.e. liquid versus tablet, and levels peak faster for liquid preparations. (Santosh P.J. 2009) Ionized drugs (many of them weak acids) may be less well absorbed from a child’s less acidic stomach. (Taylor E. 2015) 25
  • 26. METABOLISM: The normal rate of hepatic metabolism is high in children until the time of puberty. The result is that most medications are aggressively metabolized in the liver and rapidly excreted. Because what ultimately matters is how much of the drug enters the bloodstream, treatment of pre-pubertal children may require dose that approach or equal those for adults. The use of seemingly high doses for young children may seem counterintuitive to many parents, and thus it will be helpful for clinicians to explain the role of increased rate of drug metabolism. 26
  • 27. METABOLISM: During the entry into puberty, the rate of hepatic metabolism significantly slows. For this reason, youngsters who have been on a maintenance dose of psychiatric medication and tolerating it well may begin to show increasing side effects when this change in metabolic rate occurs and more of the drug begins to escape the liver and enter circulation. Dosage adjustments may then be required, to minimize side effects. (Preston et al. 2015) 27
  • 28. DISTRIBUTION: Children differ from adults in the proportions of extracellular water volume and body fat. The proportion of extracellular water decreases substantially from birth through early adolescence. Younger children have a relatively larger distribution volume for water- soluble drugs. They therefore require a relatively higher dose to achieve a comparable plasma concentration. (Johnson M.R. et al 2015) 28
  • 29. BLOOD - BRAIN BARRIER: The blood-brain barrier tends to be more permeable in children than in adults. The greater permeability of the blood-brain barrier in children may mean a greater than predicted effect. (Taylor E. 2015) 29
  • 30. EXCRETION: The main route of drug elimination is through the kidneys. Absolute clearance is usually lower in children than in adults, but weight- adjusted clearance is greater. Because of the faster elimination, the drug plasma half-life can be shorter in children than in adults. A shorter elimination half-life means that plasma steady-state is reached sooner during repeated administration, and that elimination is faster so that withdrawal symptoms upon discontinuation are more likely. In these cases, a more frequent dosing is needed to maintain consistent therapeutic levels and prevent withdrawal symptoms between doses. (Vitiello 2014) 30
  • 31. CLINICAL GUIDELINES At the starting point, while recommending psychotropic drugs, complexities of pharmacokinetic and pharmacodynamic factors have to be considered. Later in every case it is necessary to titrate the dose against the desired clinical response. Whenever possible, blood levels should be done. Some of them are very useful in monitoring the optimum dose of the drugs, e.g., lithium and anticonvulsants. Therapeutic level for : Lithium 0.6-1.2 mEq/L. Carbamazepine 8-12 ng/ml Valproic Acid 50-125 µg/ml. (Cobert 2013) 31
  • 32. PREVENTIVE MEASURES TO AVOID DRUG INTERACTION Obtain a detailed medication history including OTC drugs and compounds from alternative approaches than modern medicine. Young patients constitute high risk group. So, use drugs with minimum interaction potential. Avoid poly-pharmacy, whenever possible. Educate patient and family, include written instruction, when appropriate. Keep detailed, up-dated references on important potential drug interactions. (Konar 2005) 32
  • 33. SPECIFIC ISSUES RELATED TO PEDIATRIC PHARMACOLOGY Let us first discuss diagnosis vs. target symptom approach. At times, categorical diagnosis is easy to use; at other times, functionally impairing symptoms control may be a better approach to deal with the clinical situation. Effective pharmacotherapists should be mindful of both the target symptoms and the context and settings in which they occur. (Bostic & Rho 2006) 33
  • 34. SPECIFIC ISSUES RELATED TO PEDIATRIC PHARMACOLOGY Therapeutic alliance is slightly more complicated in children than adults. In pediatric psychopharmacology specifically, there is always at least a dual alliance, if not more, that must be acknowledged and nurtured. Prescribing clinicians should strive to include both patients and parents / grand parents / guardian into the working alliance paradigms of goal identification, tasks consolidation, and therapeutic bond establishment. (Joshi 2006) 34
  • 35. SPECIFIC ISSUES RELATED TO PEDIATRIC PHARMACOLOGY Children’s concept about medications is to be acknowledged and respected. They may be concerned about physical properties of the medication itself like form or size. Then there could be wrong kind of notions about medicine. The patient may believe that only children who are “sick” or “bad” have to take medicine. Timing of the dose and frequency (like, morning, evening or during school dosage) have to be kept in mind. Special caution must be taken in using injectable medications for children and adolescents with a history of trauma. (Joshi 2006) 35
  • 36. SPECIFIC ISSUES RELATED TO PEDIATRIC PHARMACOLOGY Comorbidity is more a rule than exception in children e.g., Intellectual Developmental Disorder, Autism, ADHD, ODD, Epilepsy, Conduct Disorder, Anxiety Disorder, Depression, they all come in different combinations. Over the last decade, pharmacotherapy in pediatric psychiatry has shown similar trends toward poly-pharmacy as in adults. Here you have to be more cautious because children have more propensity for seizure and EPS. 36
  • 37. SPECIFIC ISSUES RELATED TO PEDIATRIC PHARMACOLOGY Adverse events are more likely when multiple drugs are used, and interactions can be unpredictable. Combining drugs from the same pharmacological class is rarely indicated, except when cross-tapering while switching drugs. Combining drugs can be rational when their pharmacological actions are complementary, although the side effect burden is usually higher. 37
  • 38. SPECIFIC ISSUES RELATED TO PEDIATRIC PHARMACOLOGY Polypharmacy requires pharmacological expertise and should usually be supervised by a specialist. When advising investigations, if it is not possible to have an adequate battery done, be at least optimum. Adequate investigation may not be feasible due to financial constraints in low resource countries but important ones cannot be omitted and safety concerns may never be downplayed. So taking hints from clinical presentation, regarding adverse effects, may be more important in the context of low resource countries, when advising battery of investigation. 38
  • 39. SOME SPECIAL PRECAUTIONS First we should be committed to try to diagnose the condition to the best of our understanding and ability before we prescribe. We must remember, pharmacotherapy is only a part of treatment plan. Consideration must be given to all aspect of child’s life like psychosocial, educational and family interventions. Obtain an informed consent after discussing possible side effects and need for monitoring. Discuss black box warnings. Use the lowest possible dose. There should be frequent contact with the patient and the family. After a period of stabilization (6-12 months), evaluate the need for continued medications.39
  • 40. CONCLUSION There is great concern today that children are being over treated with medication, especially in the US. (Rapoport 2013) By contrast, many countries make so little use of medication that it seems probable that children who could benefit do not receive it. Under-treatment is perhaps a bigger problem globally than overmedication. With limited availability of professionals, the low resource countries should focus on services delivery to reach to the widest population. 40
  • 41. FIVE SIMPLE QUESTIONS IN RELATION TO CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY 1. As compared to adult, liver is: A. More Active B. Less Active 2. As compered to adult, elimination (weight adjusted clearance) through kidneys is: A. Faster B. Slower 3. Research Unit of Pediatric Psychopharmacology (RUPP) has been formed under leadership of: A. Royal College of Psychiatrist, London B. National Institute of Mental Health C. United States Food and Drug Administration 4. Blood brain barrier in children is: A. Less permeable B. More permeable 5. As compared to adult, metabolic side effects of antipsychotics are: A. More common B. Less common 41 BEFORE WORKSHOP AFTER WORKSHOP
  • 42. ANSWER SHEET 1. As compared to adult, liver is: A. More Active B. Less Active 2. As compered to adult, elimination (weight adjusted clearance) through kidneys is: A. Faster B. Slower 3. Research Unit of Pediatric Psychopharmacology (RUPP) has been formed under leadership of: A. Royal College of Psychiatrist, London B. National Institute of Mental Health C. United States Food and Drug Administration 4. Blood brain barrier in children is: A. Less permeable B. More permeable 5. As compared to adult, metabolic side effects of antipsychotics are: A. More common B. Less common 42     

Notas del editor

  1. Coghill D. and Sinita E. (2014). Pharmacology for Attention Deficit Hyperactivity Disorder, Tourette Syndrome and Autism Spectrum Disorder, Clinical Topics in Child and Adolescent Psychiatry, Huline-Dickens S. (Editor), Bell & Brain Limited, Glasgow, UK, P.74 Huline-Dickens S. (2014). Clinical Topics in Child and Adolescent Psychiatry, Huline-Dickens S.(Editor), Bell & Brain Limited, Glasgow, UK, P.XXI
  2. Correll C. U., Gerhard T. and Olfson M. (2013) Prescribing of psychotropic medications to children and adolescents: quo vadis? World Psychiatry, Volume 12, Issue 2 JUN 2013 P.127-128
  3. Stroeh O. and Trivedi H.K. (2012). Appropriate and judicious use of Psychotropic Medications in Youth, Child and Adolescent Psychiatric Clinics of North America, Oct 2012-Vol 21- Number 4.P.703-711
  4. Vitiello B. (2006). An update on publicly funded multisite trials in pediatric psychopharmacology, Child and Adolescent Psychiatric Clinic of North America Volume 15, P. 1-12
  5. Rho JM, Storey TW. (2001) Molecular ontogeny of major neurotransmitter receptor systems in the mammalian central nervous system: norepinephrine, dopamine, serotonin, acetylcholine, and glycine. Journal of Child Neurology, 16:271-279. Chugani DC, Muzik O, Juhasz C et al. (2001) Postnatal maturation of human GABAA receptors measured with positron emission tomography. Annals of Neurology, 49:618-626.
  6. Hazell P, O’Connell D, Heathcote D et al. (1995) Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. British Medical Journal, 310:897- 901. Correll CU, Manu P, Olshanskiy V et al. (2009) Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. Journal of the American Medical Association, 302:1765-1773. Hammad TA, Laughren T, Racoosin J. (2006) Suicidality in pediatric patients treated with antidepressant drugs. Archives of General Psychiatry, 63:332-339. Stone M, Laughren T, Jones ML (2009) Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. British Medical Journal, 339:b2880.
  7. Greenhill LL, Abikoff H, Chuang S et al. (2006) Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 45:1284-1293.
  8. Santosh P.J. (2009) Medication for Children and Adolescents: Current Issues, New Oxford Textbook of Psychiatry, Second Edition, Edited by Gelder M.G., Andreasen N.C, Lopez-Ibor Jr J.J. and Geddes J.R., Voloum 2, Oxford University Press, P.1793-1799 Taylor E. (2015) Pharmacological, medically–led and related treatments, Rutter’s Child and Adolescent Psychiatry, Sixth Edition, Edited by Thapar A. et al, Wiley Blackwell, Chapter-43, P.564
  9. Preston J.D., O’Neal J.H., Talaga M.C. (2015) Issue in Psychopharmacological Treatment of Children and Adolescents, Child and Asolescent Clinical Psychopharmacology Made Simple, Third Edition, New Harbinger Publications, Inc., P.9
  10. Johnson M.R., Hatzis N.M., Dulcan M.K., Crawford G.C. Cozza S.J. (2015) Treatment of Children and adolescent, Text Book of Psychiatry, Sixth Edition, Edited by Hales R.E., Yudofsky S.C., Roberts L.W., American Psychiatric Publishing, Washinton, London, P.1192
  11. Taylor E. (2015) Pharmacological, medically–led and related treatments, Rutter’s Child and Adolescent Psychiatry, Sixth Edition, Edited by Thapar A. et al, Wiley Blackwell, Chapter-43, P.564
  12. Vitiello B. (2014). Principles in Using Psychotropic Medication in Children and Adolescents, IACAPAP Text book of Child and Adolescents Mental Health, Rey Joseph M. (Editor), International Association for Child and Adolescent Psychiatry and Allied Professions, IACAPAP, Geneva. Chapter A.7, P.7-8
  13. Cobert J. (2013) Disorder of Elimination: Enuresis and Encopresis, Disorder Affecting Somatic Functions, Tarascon Pediatric Psychiatrica, Jones & Bartlett Learning, Burlington MA, P. 226-229
  14. Konar D. (2005) Mental Disorders in Children and Adolescents Needs and Strategies for Intervention edited by Savita Malhotra, CSB Publishers & Distributors. Delhi, P.132-137
  15. Bostic J.Q., Rho Y, (2006) Target symptom psychopharmacology: between the forest and trees, Child and Adolescent Psychiatric Clinic of North America, Volume 15. P. 289-302
  16. Joshi S.V. (2006) Team work: the therapeutic alliance in pediatric pharmacotherapy, Child and Adolescent Psychiatric Clinic of North America, Volume 15, P. 239-262
  17. Joshi S.V. (2006) Team work: the therapeutic alliance in pediatric pharmacotherapy, Child and Adolescent Psychiatric Clinic of North America, Volume 15, P. 239-262
  18. Rapoport J.L. (2013) Pediatric Psychopharmacology: too much or too little? World Psychiatry: 12(2):118-123